Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Petr Jarolim, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Petr Jarolim and David Morrow.
Connection Strength

7.480
  1. Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. Diabetes Care. 2018 07; 41(7):1510-1515.
    View in: PubMed
    Score: 0.792
  2. Use of high sensitivity cardiac troponin assays as an adjunct to cardiac stress testing. Clin Biochem. 2016 Apr; 49(6):419-420.
    View in: PubMed
    Score: 0.679
  3. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care. 2021 Sep 17.
    View in: PubMed
    Score: 0.249
  4. A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. J Am Coll Cardiol. 2021 Aug 10; 78(6):634-636.
    View in: PubMed
    Score: 0.247
  5. Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation. 2021 Jul 20; 144(3):249-251.
    View in: PubMed
    Score: 0.246
  6. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2021 05 01; 42(17):1698-1706.
    View in: PubMed
    Score: 0.242
  7. Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50. J Am Heart Assoc. 2021 05 04; 10(9):e018673.
    View in: PubMed
    Score: 0.242
  8. Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiol. 2020 11 01; 5(11):1255-1262.
    View in: PubMed
    Score: 0.234
  9. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. J Am Coll Cardiol. 2019 08 27; 74(8):1057-1068.
    View in: PubMed
    Score: 0.216
  10. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS. Clin Chem Lab Med. 2019 06 26; 57(7):1084-1092.
    View in: PubMed
    Score: 0.213
  11. Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes. J Am Heart Assoc. 2019 05 07; 8(9):e011444.
    View in: PubMed
    Score: 0.211
  12. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019 02 05; 139(6):760-771.
    View in: PubMed
    Score: 0.208
  13. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab. 2017 07; 19(7):962-969.
    View in: PubMed
    Score: 0.182
  14. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921.
    View in: PubMed
    Score: 0.182
  15. Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 Dec 01; 1(9):989-998.
    View in: PubMed
    Score: 0.179
  16. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol. 2016 Dec 01; 1(9):999-1006.
    View in: PubMed
    Score: 0.179
  17. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clin Chem. 2017 Jan; 63(1):307-315.
    View in: PubMed
    Score: 0.178
  18. Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T. Clin Cardiol. 2015 Apr; 38(4):230-5.
    View in: PubMed
    Score: 0.158
  19. Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. Eur Heart J Acute Cardiovasc Care. 2015 Oct; 4(5):431-40.
    View in: PubMed
    Score: 0.156
  20. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). J Am Coll Cardiol. 2014 Apr 29; 63(16):1644-53.
    View in: PubMed
    Score: 0.147
  21. Diagnostic performance of copeptin in patients with acute nontraumatic chest pain: BWH-TIMI ED chest pain study. Clin Cardiol. 2014 Apr; 37(4):227-32.
    View in: PubMed
    Score: 0.146
  22. Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. J Thromb Thrombolysis. 2013 Nov; 36(4):361-7.
    View in: PubMed
    Score: 0.144
  23. Erratum to: Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. J Thromb Thrombolysis. 2013 Nov; 36(4):368.
    View in: PubMed
    Score: 0.144
  24. Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. Clin Chem. 2014 Jan; 60(1):158-64.
    View in: PubMed
    Score: 0.143
  25. Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study. Eur Heart J Acute Cardiovasc Care. 2013 Sep; 2(3):195-202.
    View in: PubMed
    Score: 0.143
  26. Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. J Thromb Thrombolysis. 2012 Aug; 34(2):229-34.
    View in: PubMed
    Score: 0.132
  27. Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2012 Jul 24; 60(4):332-8.
    View in: PubMed
    Score: 0.132
  28. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012 Jan; 58(1):267-73.
    View in: PubMed
    Score: 0.126
  29. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J. 2011 Mar; 32(6):697-705.
    View in: PubMed
    Score: 0.118
  30. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol. 2010 Mar 23; 55(12):1189-1196.
    View in: PubMed
    Score: 0.112
  31. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol. 2007 Aug; 128(2):282-6.
    View in: PubMed
    Score: 0.093
  32. Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest. 2007 Apr; 131(4):964-71.
    View in: PubMed
    Score: 0.091
  33. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA. 2005 Dec 14; 294(22):2866-71.
    View in: PubMed
    Score: 0.083
  34. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681.
    View in: PubMed
    Score: 0.060
  35. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. Eur J Heart Fail. 2021 06; 23(6):1026-1036.
    View in: PubMed
    Score: 0.059
  36. Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States. Crit Pathw Cardiol. 2019 03; 18(1):1-4.
    View in: PubMed
    Score: 0.052
  37. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial. Eur J Heart Fail. 2019 04; 21(4):462-470.
    View in: PubMed
    Score: 0.052
  38. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 06 01; 3(6):473-480.
    View in: PubMed
    Score: 0.050
  39. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10).
    View in: PubMed
    Score: 0.047
  40. Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. J Am Coll Cardiol. 2016 07 19; 68(3):322-323.
    View in: PubMed
    Score: 0.043
  41. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2016 05 20; 5(5).
    View in: PubMed
    Score: 0.043
  42. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. Circulation. 2015 Oct 13; 132(15):e198.
    View in: PubMed
    Score: 0.041
  43. Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". Circulation. 2015 Aug 11; 132(6):e121-2.
    View in: PubMed
    Score: 0.041
  44. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 06; 385(9984):2288-95.
    View in: PubMed
    Score: 0.040
  45. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014 Oct 28; 130(18):1579-88.
    View in: PubMed
    Score: 0.038
  46. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. 2014 Jun 10; 63(22):2421-8.
    View in: PubMed
    Score: 0.037
  47. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012 Jan 17; 125(2):233-40.
    View in: PubMed
    Score: 0.032
  48. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009 Feb; 55(2):265-73.
    View in: PubMed
    Score: 0.026
  49. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J. 2009 Jan; 30(2):162-9.
    View in: PubMed
    Score: 0.026
  50. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol. 2007 Nov 27; 50(22):2117-24.
    View in: PubMed
    Score: 0.024
  51. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006 Jun 06; 47(11):2326-31.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.